A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology

Immunologic Research

Volumn 46, Issue 1-3, 2010, Pages 59-71

  Abrams, Scott I ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Host tumor interactions; Immunosuppression; Immunotherapy; Interferon regulatory factor 8; Myeloid derived suppressor cells; Tumor escape; Tumor immunity; Tumor microenvironment

Indexed keywords

FAS ANTIGEN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN;

APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER THERAPY; CELL MATURATION; CYTOLOGY; CYTOLYSIS; ENZYME REGULATION; GENE EXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOSURVEILLANCE; LUNG METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR ESCAPE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; HUMANS; INTERFERON REGULATORY FACTORS; MYELOID CELLS; NEOPLASMS;

EID: 77949342144     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8125-6     Document Type: Article

References (41)

1. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41-51.
2. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-83.
3. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene. 2008;27:5894-903.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
5. Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene. 2003;22:8634-44.
6. Abrams SI. Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front Biosci. 2005;10:809-21.
7. Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol. 2003;171:2402-12.
8. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol. 2006;176:3374-82.
9. Liu K, Abrams SI. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol. 2003;170:5973-80.
10. Liu K, Caldwell SA, Abrams SI. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res. 2005;65:4376-88.
11. Liu K, McDuffie E, Abrams SI. Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol. 2003;171:4164-74.
12. Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. J Immunol. 2003;170:6329-37.
13. Tamura T, Ozato K. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res. 2002;22:145-52.
14. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535-84.
15. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-17.
16. Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001;97:3648-50.
17. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22-9.
18. Egwuagu CE, Li W, Yu CR, Che Mei Lin M, Chan CC, Nakamura T, et al. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene. 2006;25:3670-9.
19. Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene. 2008;27:5267-76.
20. Stewart, TJ, Greeneltch, KM, Reid, JE, Liewehr, DJ, Steinberg, SM, Liu, K, Abrams, SI. Interferon Regulatory Factor-8 Modulates the Development of Tumor-Induced CD11bGr-1 Myeloid Cells. J Cell Mol Med. 2009 [Epub ahead of print].
21. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
22. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499-506.
23. Masumi A, Tamaoki S, Wang IM, Ozato K, Komuro K. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett. 2002;531:348-53.
24. Wang IM, Contursi C, Masumi A, Ma X, Trinchieri G, Ozato K. An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J Immunol. 2000;165:271-9.
25. Kim YM, Im JY, Han SH, Kang HS, Choi I. IFN-gamma up-regulates IL-18 gene expression via IFN consensus sequence-binding protein and activator protein-1 elements in macrophages. J Immunol. 2000;165:3198-205.
26. Liu J, Ma X. Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and PU.1. J Biol Chem. 2006;281:19188-95.
27. Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P, et al. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med. 1999;190:411-21.
28. Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood. 2004;103:3480-9.
29. Huang W, Zhu C, Wang H, Horvath E, Eklund EA. The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem. 2008;283:7921-35.
30. Krammer PH, Galle PR, Moller P, Debatin KM. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res. 1998;75:251-73.
31. Moller P, Koretz K, Leithauser F, Bruderlein S, Henne C, Quentmeier A, et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer. 1994;57:371-7.
32. Leibovitz A, Stinson JC, McCombs WB III, McCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976;36:4562-9.
33. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, et al. Validation of a model of colon cancer progression. J Pathol. 2000;192:446-54.
34. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954-61.
35. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology. 2003;109:300-7.
36. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113-26.
37. Stewart TJ, Lutsiak ME, Abrams SI. Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma. Cancer Invest. 2008;26:237-49.
38. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1-50.
39. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836-48.
40. Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, et al. Host immuno-surveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res. 2007;67:10406-16.
41. Yang D, Wang S, Brooks C, Dong Z, Schoenlein PV, Kumar V, et al. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res. 2009;69:1080-8.